Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-262.64M |
| Operating Margin | 0.00% |
| Return on Equity | -115.80% |
| Return on Assets | -44.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.16 |
| Price-to-Book | 9.27 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $94.80M |
| Float | $68.21M |
| % Insiders | 1.64% |
| % Institutions | 104.76% |
Volatility is currently expanding
The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.
Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70.
New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026
If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the “Class Period”).
Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns. NEW YORK, Oct. 1, 2026 /PRNewswire/ -- SueWallSt alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action brought on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial designs the FDA had already questioned, including response criteria the agency said were not consistent with RECIST v1.1. NEW YORK, Sept.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REPL and any ticker you trade — then tracks every position and per-strategy win rate.
